DrKenneth Cusi

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants with Metabolic Dysfunction-Associated Steatotic Liver Disease who are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes)

Improving Screening and Guideline Implementation for People Living with Obesity and Type 2 Diabetes and at Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Phase 2b Randomized, Double-blinded, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Maridebart Cafraglutidee in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight

Evaluating the Impact of Integrating Optimal Reflexive MASH Care Pathways Within the Electronic Health Record

WISE II - Obesity and Type-2 Diabetes: Bariatric Surgery Effects on Brain Function

“A Phase 3, randomized, bouble-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus.”

A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)

U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS

Esterase-Sensitive Hyperpolarized 13C Probes for Simultaneous Imaging of pH and Energy Metabolism

Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH

A randomized, double-blind, placebo-controlled, parallel group trial to assess the efficacy and safety of PXL770 versus placebo after 12 weeks of treatment in patients with Nonalcoholic Fatty Liver Disease (NAFLD) with or without type 2 diabetes mellitus

Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC) NOD Study

Novel pathways in the pathogenesis and pathophysiology of NAFLD in Hispanics

Developing a VCTE-based Screening Model for Patients with Type 2 Diabetes and Advanced Fibrosis

Efficacy, Safety and Mechanism of Action of lanifibranor (IVA337) in patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Ivier disease (NAFLD)

Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)

Miscellaneous Donors Project

A Phase 2, prospective, multi-center, double-blind, randomized study of Saroglitazar Magnesium, 1 mg, 2 mg, or 4 mg versus placebo in patients with non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH).

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis (NASH). A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients with NASH

5-year longitudinal observational study of patients with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.

A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (NASH)

Imaging Hepatic Gluconeogenesis with Hyperpolarized Dihydroxyacetone

Developing a Novel Screening Strategy in Overweight & Obese Children at Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)